Trials / Completed
CompletedNCT01606059
Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition
A Randomized, Open Label, 2-treatment, 2-sequence, Cross-over Study to Compare the Safety and Pharmacokinetics of DW-0919 and DW-0920 After Single Oral Administration in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety and pharmacokinetics of DW-0919 and DW-0920 in healthy male volunteers under fasting condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DW-0920 | Dosage form: Extended release tablet Dosage: 2 tablets |
| DRUG | DW-0919 | Dosage form: Extended release tablet Dosage: 1 tablet |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-05-25
- Last updated
- 2016-10-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01606059. Inclusion in this directory is not an endorsement.